Abstract
Inflammatory breast cancer (IBC) is a relatively rare and aggressive subtype, accounting for nearly 2.5% of all diagnosed breast cancers worldwide. It is usually characterised by an acute onset, rapid clinical progression, poor prognosis and micrometastasis at the time of presentation. Prompt recognition of clinical symptoms and identification of warning signs are vital in diagnosing and appropriately treating a patient with IBC.
2016 BMJ Publishing Group Ltd.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / therapy
-
Capecitabine / therapeutic use
-
Female
-
Humans
-
Inflammatory Breast Neoplasms / diagnosis*
-
Inflammatory Breast Neoplasms / drug therapy
-
Lapatinib
-
Middle Aged
-
Neoplasms, Second Primary / diagnosis*
-
Neoplasms, Second Primary / drug therapy*
-
Paclitaxel / therapeutic use
-
Prognosis
-
Quinazolines / therapeutic use
Substances
-
Quinazolines
-
Lapatinib
-
Capecitabine
-
Paclitaxel